These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 12894189)

  • 1. Hybrid vigor.
    Williams K
    Nat Biotechnol; 2003 Aug; 21(8):843. PubMed ID: 12894189
    [No Abstract]   [Full Text] [Related]  

  • 2. Hybrid rigor mortis.
    Nat Biotechnol; 2003 Jun; 21(6):585. PubMed ID: 12776128
    [No Abstract]   [Full Text] [Related]  

  • 3. New biotech hubs may emerge as industry matures.
    Basu P
    Nat Biotechnol; 2003 Oct; 21(10):1123. PubMed ID: 14520385
    [No Abstract]   [Full Text] [Related]  

  • 4. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 5. Hidden in plain view.
    Jacobs T
    Nat Biotechnol; 2003 Jun; 21(6):603. PubMed ID: 12776141
    [No Abstract]   [Full Text] [Related]  

  • 6. Giving your spinout the right spin.
    McElroy D
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE39-41. PubMed ID: 12874978
    [No Abstract]   [Full Text] [Related]  

  • 7. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 8. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 9. Financial planning for your practice.
    Schumann TC
    J Mich Dent Assoc; 2009 Feb; 91(2):22. PubMed ID: 19288659
    [No Abstract]   [Full Text] [Related]  

  • 10. Start-ups weigh benefits of corporate incubators.
    Waltz E
    Nat Biotechnol; 2008 Mar; 26(3):254-5. PubMed ID: 18327219
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotechs feel the pain.
    Ledford H
    Nature; 2009 Jan; 457(7226):136-7. PubMed ID: 19129814
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term financial stability is a goal at the ADA.
    Engel D
    J Mich Dent Assoc; 2012 Jul; 94(7):22. PubMed ID: 22970499
    [No Abstract]   [Full Text] [Related]  

  • 13. Antisoma-Roche deal--a new kind of buyout?
    Mitchell P
    Nat Biotechnol; 2003 Jan; 21(1):3. PubMed ID: 12511894
    [No Abstract]   [Full Text] [Related]  

  • 14. "Good to great" in healthcare: how some organizations are elevating their performance.
    Pieper SK
    Healthc Exec; 2004; 19(3):20-6. PubMed ID: 15146726
    [No Abstract]   [Full Text] [Related]  

  • 15. The stampede to convertibles.
    Jacobs T
    Nat Biotechnol; 2003 Aug; 21(8):855. PubMed ID: 12894195
    [No Abstract]   [Full Text] [Related]  

  • 16. Commercializing nanotechnology.
    Mazzola L
    Nat Biotechnol; 2003 Oct; 21(10):1137-43. PubMed ID: 14520392
    [No Abstract]   [Full Text] [Related]  

  • 17. Investing in nanotechnology.
    Paull R; Wolfe J; Hébert P; Sinkula M
    Nat Biotechnol; 2003 Oct; 21(10):1144-7. PubMed ID: 14520393
    [No Abstract]   [Full Text] [Related]  

  • 18. Focus on efficiency.
    Ishimoto CJ
    Hawaii Dent J; 1997 Apr; 28(4):16, 18. PubMed ID: 11851232
    [No Abstract]   [Full Text] [Related]  

  • 19. Biotechnology financing dilemmas and the role of special purpose entities.
    Schiff L; Murray F
    Nat Biotechnol; 2004 Mar; 22(3):271-7. PubMed ID: 14990945
    [No Abstract]   [Full Text] [Related]  

  • 20. Investments pay off with financial information systems. CFOs are more involved than ever in missions to integrate clinical data with financial data, and then mine it to maximize financial outcomes.
    Rogoski RR
    Health Manag Technol; 2004 Aug; 25(8):14-5, 17. PubMed ID: 15328955
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.